<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.peertechzpublications.org/assets/xsl/oaitohtml.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
										<responseDate>2026-05-15T14:09:56Z</responseDate>
										<request verb="GetRecord" metadataPrefix="oai_dc" identifier="oai:www.peertechzpublications.org:10.17352/jgro.000040">https://www.peertechzpublications.org/oai-pmh</request><GetRecord><record>
								<header>
									<identifier>oai:www.peertechzpublications.org:10.17352/jgro.000040</identifier>
									<datestamp>2017-05-25</datestamp>
									<setSpec>PTZ.JGRO:VOL3</setSpec>
								</header>
								<metadata>
									<oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
										<dc:title>
										Biological Analyses for Characterization of the Uterine Sarcoma Using Mouse Model
										</dc:title><dc:creator>Takuma Hayashi</dc:creator><dc:creator> Tomoyuki Ichimura</dc:creator><dc:creator> Mari Kasai</dc:creator><dc:creator> Yae Kanai</dc:creator><dc:creator> Hirofumi Ando</dc:creator><dc:creator> Koichi Ida</dc:creator><dc:creator> Nobuo Yaegashi</dc:creator><dc:creator> Susumu Tonegawa</dc:creator><dc:creator>Ikuo Konishi</dc:creator><dc:description>&lt;p&gt;Uterine sarcomas are neoplastic malignancies that typically arise in tissues of a mesenchymal origin
in uterine body. The identifi cation of novel molecular mechanisms leading to sarcoma formation, and the
establishment of new therapies and biomarkers has been hampered by several critical factors. Uterine
leiomyosarcoma (U-LMS), which is the most common sarcoma, is rarely observed in clinical settings, with
fewer than 15,000 new cases being diagnosed each year in the United States. Another complicating factor
is that U-LMS are extremely heterogeneous as they arise in a multitude of tissues from many different cell
lineages. The scarcity of clinical samples coupled with its inherent heterogeneity creates a challenging
experimental environment for clinicians and scientists. Faced with these challenges, there have been
extremely limited advances in treatment options available to patients with U-LMS compared with those for
patients with other malignant tumors. In order to glean insight into the pathobiology of U-LMS, scientists
are now using mouse models whose genomes have been specifically tailored to carry gene deletions, gene
amplifications, and point mutations commonly observed in human soft tissue sarcomas. The use of these
model organisms has been successful in increasing our knowledge and understanding of how alterations
in relevant oncogenic, tumor suppressive, and signaling pathways directly impact sarcomagenesis. It is the
aim of many in the biological community that the use of these genetically modified mouse models will serve
as powerful in vivo tools to further our understanding of sarcomagenesis and potentially identify novel
biomarkers and develop therapeutic strategies.&amp;nbsp;&lt;/p&gt;</dc:description>
										<dc:publisher>Journal of Gynecological Research and Obstetrics - Peertechz Publications</dc:publisher>
										<dc:date>2017-05-25</dc:date>
										<dc:type>Short Communication</dc:type>
										<dc:identifier>https://doi.org/10.17352/jgro.000040</dc:identifier>
										<dc:language>en</dc:language>
										<dc:rights>Copyright © Takuma Hayashi et al.</dc:rights>
									</oai_dc:dc>
								</metadata>
							</record></GetRecord>
						</OAI-PMH>
